SynthesisFrontiers in oncology2020
The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review.
Synthesis in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Serum Proteomic Signatures of Pregnancy-associated Breast Cancer.Cancer genomics & proteomics · 2025Article
- SP110 Could be Used as a Potential Predictive and Therapeutic Biomarker for Oral Cancer.Molecular biotechnology · 2025Article
- Mechanism of the KIAA1429/KLF1/PD-L1 Axis in Regulating Immune Escape in Non-small Cell Lung Cancer.Cell biochemistry and biophysics · 2025Article
- Alterations in the Epigenetic Machinery Associated with Prostate Cancer Health Disparities.Cancers · 2023Article
- Breast Carcinogenesis during Pregnancy: Molecular Mechanisms, Maternal and Fetal Adverse Outcomes.Biology · 2023Review
- Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge.Diagnostics (Basel, Switzerland) · 2023Review
- The diagnostic significance of the ZNF gene family in pancreatic cancer: a bioinformatics and experimental study.Frontiers in genetics · 2023Article
- Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Article
- Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study.BMC cancer · 2022Article
- Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission.Frontiers in genetics · 2022Article
- Dissecting the Roles of PDCD4 in Breast Cancer.Frontiers in oncology · 2022Review
- Clinicopathologic features, treatment, and prognosis of pregnancy-associated breast cancer.Frontiers in oncology · 2022Article
- Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.Breast cancer research and treatment · 2021Article
- Germline mutations in a clinic-based series of pregnancy associated breast cancer patients.BMC cancer · 2021Article
- Is It Possible to Personalize the Diagnosis and Treatment of Breast Cancer during Pregnancy?Journal of personalized medicine · 2020Review
- Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy.Cancers · 2020Review
- Review
- Chasing Hippos: Implications of YAP1 and TAZ Expression in Pregnancy-associated Breast Cancer Tumorigenesis.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignancy diagnosed during pregnancy. Strong data on the genomic profile of pregnancy-associated breast cancer are lacking. This systematic review aims to integrate and analyze all existing data from the literature regarding the genomic background and the gene mutational patterns of pregnancy-associated breast cancer. Using various genomic analysis methods, multiple differentially expressed genes and numerous non-silent mutations have been detected. More particularly, our review demonstrates the aberrant expression of several oncogenes (e.g.,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.